<DOC>
	<DOCNO>NCT03002519</DOCNO>
	<brief_summary>This study aim evaluate safety intramuscular ( IM ) administration PLX-R18 subject incomplete hematopoietic recovery follow HCT .</brief_summary>
	<brief_title>A Study Evaluate Safety Intramuscular Injections PLX-R18 Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation</brief_title>
	<detailed_description />
	<criteria>1 . Age ≥18 year . 2 . At least 6 month HCT . 3 . Sustained platelet count ≤50,000/µL and/or sustain Hgb ≤8 g/dL , related nature graft . 4 . Stable donor cell chimerism . 5 . If subject allogeneic HCT malignant disease , subject complete donor chimerism . 6 . ANC ≥1,000/mm3 time screen . 7 . General performance status evaluate Eastern Cooperative Oncology Group 02 scale . 8 . Signed write informed consent . 1 . Evidence active malignancy time HCT time since HCT . 2 . Other known etiology thrombocytopenia ( infection , medication , etc. ) . 3 . Other known etiology anemia ( blood loss , iron deficiency , etc. ) . 4 . Current active infection require systemic treatment . 5 . Acute graft versus host disease ( GvHD ) Grade III IV , severe chronic GvHD time screen . 6 . Treatment cytokine , include thrombopoietin , erythropoietin , granulocyte colony stimulate factor ( GCSF ) , granulocytemacrophage colony stimulate factor ( GMCSF ) last 4 week prior treatment , currently plan subject . 7 . Subject receive prophylactic treatment donor lymphocyte infusion ( DLI ) within 6 month prior treatment , cell therapy within 3 month prior treatment . 8 . History malignancy ( disease require HCT ) within 5 year prior screen . 9 . History significant transfusion reaction . 10 . Known allergy follow : dimethyl sulfoxide ( DMSO ) , human serum albumin , bovine serum albumin , gentamicin , antihistamine . 11 . History allergic/hypersensitivity reaction substance require hospitalization and/or treatment intravenous steroids/epinephrine . 12 . Medical history human immunodeficiency virus syphilis infection . 13 . Known active hepatitis B hepatitis C infection time screen . 14 . A pregnant lactating woman woman plan become pregnant study . 15 . Serum Creatinine level &gt; 2.5 mg/dL . 16 . Serum glutamic pyruvic transaminase ( alanine aminotransferase ) , serum oxaloacetic pyruvic transaminase ( aspartate aminotransferase ) &gt; 2.5 x upper limit normal range . 17. International normalized ration ( INR ) &gt; 2 subject oral anticoagulant therapy INR &gt; 2 unless anticoagulation treatment safely interrupted/discontinued around investigational product ( IP ) treatment . 18 . Severe uncontrolled/unstable cardiac , pulmonary , renal disease , include myocardial infarction cerebrovascular accident within 3 month prior treatment . 19 . History solid organ transplantation . 20 . Signs symptoms active central nervous system disease . 21 . Life expectancy &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>